PURPOSE: To demonstrate transdermal delivery of interferon alpha-2b (IFNalpha2b) in hairless rats through aqueous microchannels (micropores) created in the skin and enhanced by iontophoresis. MATERIALS AND METHODS: The Altea Therapeutics PassPort System was configured to form an array of micropores (2.0 cm(2); 72 micropores/cm(2)) on the rat abdomen. The transdermal patch (Iomed TransQ1-GS-hydrogel) was saturated with an IFNalpha2b solution (600 microg/ml) and applied for 4 h. Delivery was evaluated with and without cathodic iontophoresis (0.1 mA/cm(2)). Intravenous delivery (0.4 microg/100 g body weight) was performed to support pharmacokinetic calculations. RESULTS: IFNalpha2b was not delivered through intact skin by itself (passive delivery) or during iontophoresis. However, passive delivery through micropores was achieved in vivo in rats. A dose of 397 +/- 67 ng was delivered over 6 h, with steady state serum concentrations reaching a plateau at 1 h post-patch application. These levels dropped rapidly after patch removal, and returned to baseline within 2 h of patch removal. Iontophoresis-enhanced delivery through micropores resulted in a two-fold increase in the dose delivered (722 +/- 169 ng) in the hairless rat. CONCLUSIONS: In vivo delivery of IFNalpha2b was demonstrated through micropores created in the outer layer of the skin. Iontophoresis enhanced delivery through microporated skin in hairless rats.
PURPOSE: To demonstrate transdermal delivery of interferon alpha-2b (IFNalpha2b) in hairless rats through aqueous microchannels (micropores) created in the skin and enhanced by iontophoresis. MATERIALS AND METHODS: The Altea Therapeutics PassPort System was configured to form an array of micropores (2.0 cm(2); 72 micropores/cm(2)) on the rat abdomen. The transdermal patch (Iomed TransQ1-GS-hydrogel) was saturated with an IFNalpha2b solution (600 microg/ml) and applied for 4 h. Delivery was evaluated with and without cathodic iontophoresis (0.1 mA/cm(2)). Intravenous delivery (0.4 microg/100 g body weight) was performed to support pharmacokinetic calculations. RESULTS: IFNalpha2b was not delivered through intact skin by itself (passive delivery) or during iontophoresis. However, passive delivery through micropores was achieved in vivo in rats. A dose of 397 +/- 67 ng was delivered over 6 h, with steady state serum concentrations reaching a plateau at 1 h post-patch application. These levels dropped rapidly after patch removal, and returned to baseline within 2 h of patch removal. Iontophoresis-enhanced delivery through micropores resulted in a two-fold increase in the dose delivered (722 +/- 169 ng) in the hairless rat. CONCLUSIONS: In vivo delivery of IFNalpha2b was demonstrated through micropores created in the outer layer of the skin. Iontophoresis enhanced delivery through microporated skin in hairless rats.
Authors: Siôn A Coulman; James C Birchall; Aneesh Alex; Marc Pearton; Bernd Hofer; Conor O'Mahony; Wolfgang Drexler; Boris Považay Journal: Pharm Res Date: 2010-05-13 Impact factor: 4.200
Authors: Katarzyna Migalska; Desmond I J Morrow; Martin J Garland; Raj Thakur; A David Woolfson; Ryan F Donnelly Journal: Pharm Res Date: 2011-03-25 Impact factor: 4.200
Authors: Javier O Morales; Kristin R Fathe; Ashlee Brunaugh; Silvia Ferrati; Song Li; Miguel Montenegro-Nicolini; Zeynab Mousavikhamene; Jason T McConville; Mark R Prausnitz; Hugh D C Smyth Journal: AAPS J Date: 2017-02-13 Impact factor: 4.009
Authors: Ying Jiang; Azizi Ray; Mohammad Shajid Ashraf Junaid; Sonalika Arup Bhattaccharjee; Kayla Kelley; Ajay K Banga; Bruce E Blough; Kevin S Murnane Journal: Drug Deliv Transl Res Date: 2020-02 Impact factor: 4.617